tiprankstipranks
Advertisement
Advertisement

MX:GSKN Stock Latest News

GSK’s ViiV Healthcare announces FDA approval of Tivicay PD
The FlyGSK’s ViiV Healthcare announces FDA approval of Tivicay PD
5d ago
GSK
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
PremiumThe Fly
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
6d ago
GSK
AnaptysBio price target lowered to $70 from $75 at TD Cowen
PremiumThe Fly
AnaptysBio price target lowered to $70 from $75 at TD Cowen
6d ago
GSK
ANAB
GSK announces Japan’s MHLW approved Hibsago
PremiumThe Fly
GSK announces Japan’s MHLW approved Hibsago
7d ago
GSK
GSK announces FDA accepted for priority review a sBLA for Jemperli
PremiumThe Fly
GSK announces FDA accepted for priority review a sBLA for Jemperli
7d ago
GSK
Trump Trade: President signs EO to split up of childhood vaccines
PremiumThe FlyTrump Trade: President signs EO to split up of childhood vaccines
20d ago
AZN
EBS
Trump signs EO to split up of childhood vaccines, Bloomberg reports
Premium
The Fly
Trump signs EO to split up of childhood vaccines, Bloomberg reports
21d ago
AZN
EBS
Trump Trade: U.S. issues 15% duty on products made from polysilicon
Premium
The Fly
Trump Trade: U.S. issues 15% duty on products made from polysilicon
24d ago
AZN
EBS
Trump admin plans to issue executive order on vaccines, autism, Bloomberg says
PremiumThe Fly
Trump admin plans to issue executive order on vaccines, autism, Bloomberg says
24d ago
AZN
EBS
GSK closer to relaunching Brexafemme, says Brookline
PremiumThe Fly
GSK closer to relaunching Brexafemme, says Brookline
1M ago
GSK
SCYX
GSK price target raised to 2,000 GBp from 1,950 GBp at Deutsche Bank
PremiumThe Fly
GSK price target raised to 2,000 GBp from 1,950 GBp at Deutsche Bank
1M ago
GSK
Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV
PremiumThe Fly
Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV
1M ago
GSK
GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
PremiumRatingsGSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
1M ago
GSK
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
Premium
Ratings
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
1M ago
GSK
GlaxoSmithKline Earnings Call Highlights Record Infrastructure
Premium
Company Announcements
GlaxoSmithKline Earnings Call Highlights Record Infrastructure
1M ago
GSK
Morning Movers: Corning sinks and Boeing gains after quarterly results
PremiumThe Fly
Morning Movers: Corning sinks and Boeing gains after quarterly results
1M ago
BA
KO
GSK sees 2031 sales over GBP 40B
PremiumThe Fly
GSK sees 2031 sales over GBP 40B
1M ago
GSK
GSK sees 70p per share dividend for FY26
PremiumThe Fly
GSK sees 70p per share dividend for FY26
1M ago
GSK
GSK initiates ‘Accelerate Growth’ program
PremiumThe Fly
GSK initiates ‘Accelerate Growth’ program
1M ago
GSK
GSK reports Q2 core EPS 50.5p, up 9% at CER
PremiumThe FlyGSK reports Q2 core EPS 50.5p, up 9% at CER
1M ago
GSK
GSK sees FY26 core EPS growth 7%-9%
Premium
The Fly
GSK sees FY26 core EPS growth 7%-9%
1M ago
GSK
GSK’s ViiV Healthcare presents data from Phase IIIb VOGUE study
Premium
The Fly
GSK’s ViiV Healthcare presents data from Phase IIIb VOGUE study
1M ago
GSK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >